Immunogenic cancer peptides and uses thereof

Details Immunogenic cancer peptides and uses thereof Immunogenic cancer peptides and uses thereof

2005-05-10

2005-05-10

Brusca, John (Department: 1631)

Data processing: measuring, calibrating, or testing

Measurement system in a specific environment

Biological or biochemical

C424S085100, C424S085200, C424S093710, C424S184100, C530S322000, C702S020000

Reexamination Certificate

active

06892140

ABSTRACT:
This invention relates to novel general methods and compositions that provide cancer-specific or highly cancer-associated antigens useful for diagnosis and treatment of cancer.

REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4585742 (1986-04-01), Bernal
patent: 5194254 (1993-03-01), Barber et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5616477 (1997-04-01), Price
patent: 5620955 (1997-04-01), Knight et al.
patent: 5736517 (1998-04-01), Bogden et al.
patent: 5750110 (1998-05-01), Prieels et al.
patent: 5763164 (1998-06-01), Calenoff
patent: 5770721 (1998-06-01), Ershov et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5817637 (1998-10-01), Weiner et al.
patent: 5830876 (1998-11-01), Weiner et al.
patent: 5837251 (1998-11-01), Srivastava
patent: 5851756 (1998-12-01), Steinman et al.
patent: 5861247 (1999-01-01), Mirzabekov et al.
patent: 5871756 (1999-02-01), Jeffcoat et al.
patent: 5876735 (1999-03-01), Reed
patent: 5876966 (1999-03-01), Reed
patent: 5942235 (1999-08-01), Paoletti
patent: 5962320 (1999-10-01), Robinson
patent: 5981505 (1999-11-01), Weiner et al.
patent: 5981706 (1999-11-01), Wallen et al.
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6013268 (2000-01-01), Reed
patent: 6030618 (2000-02-01), Srivastava
patent: 6051237 (2000-04-01), Paterson
patent: 6063384 (2000-05-01), Morrow et al.
patent: 6077663 (2000-06-01), Curiel et al.
patent: 6080399 (2000-06-01), Gajewski et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 6106829 (2000-08-01), He et al.
patent: 6136315 (2000-10-01), Srivastava
Taylor-Papadimitriou et al., Exploiting altered glycosylation patterns in cancer; progress and challenges in diagnosis and therapy. TIBTECH, Jun. 1994, vol. 12, pp. 227-233.*
Hopp et al., Prediction of protein antigenic determinants from amino acid sdquences. Proc. Natl. Acad. Sci. USA, vol. 78, pp. 3824-3828, 1981.*
Barratt-Boyes, S.M., et al. (1998) “Chimpanzee Dendritic Cells Derived In Vitro from Blood Monocytes and Pulsed with Antigen Elicit Specific Immune Responses In Vivo. ” Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Antigen Processing and Presentation.J. Immunother.21(2): 142-148.
Begum, N.A. et al. (1995) “Differential Display and Integrin Alpha 6 Messenger RNA Overexpression in Hepatocellular Carcinoma.”Hepatology.22(5): 1447-1455.
Bonkhoff, H. (1998) “Analytical Molecular Pathology of Epithelial-Stromal Interactions in the Normal and Neoplastic Prostate.”Anal. Quant. Cytol. Histol.20(5): 437-442.
Brame, C.J. et al. (1999) “Identification of Extremely Reactive γ-Ketoaldehydes (Isolevuglandins) as Products of the Isoprostane Pathway and Characterization of Their Lysyl Protein Adducts.”J. Biol. Chem.274(19): 1319-1346.
Bryden, A.A.G., et al. (1999) “Paradoxical Expression of E-Cadherin in Prostatic Bone Metastases.”BJU Int.84(9): 1032-1034.
Cheever, M.A., et al. (1997) “Therapy with Cultured T Cells: Principles Revisited.”Immunol Rev.157: 177-194.
Cress, A.E., et al. (1995) “The α6β1 and α6β4 Integrins in Human Prostate Cancer Progression.”Cancer Metastasis Revs.14(3): 219-228.
Damiano, J.S. et al., (1999) “Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines.”Blood93(5): 1658-1667.
Damjanovich, L. et al. (1997) “Integrin Expression on Normal and Neoplastic Human Breast Epithelium.”Acta Chir. Hung.36(1-4): 69-71.
Disis, M.L. et al. (1999) “Generation of Immunity to the HER-2
eu Oncogenic Protein in Patients with Breast and Ovarian Cancer using a Peptide-based Vaccine.”Clin. Cancer Res.5(6): 1289-1297.
Disis, M.L., et al. (1997) “HER-2
eu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer.”Advances in Cancer Research344-370.
Disis, M.L. et al. (1998) “HER-2
eu Oncogenic Protein: Issues in Vaccine Development.”Crit. Revs. Immunol.18(1-2): 37-45.
Disis, M.L. et al. (1998) “Human HER-2
eu Protein Immunization Circumvents Tolerance to Rat neu: A Vaccine Strategy for “Self” Tumour Antigens.”Immunology93(2): 192-199.
Dong, J-T., et al. (1996) “Down-Regulation of the KAII Metastasis Suppressor Gene during the Progression of Human Prostatic Cancer Infrequently Involves Gene Mutation or Allelic Loss.”Cancer Res.56(19): 4387-4390.
Ekblom, M., et al. (1998) “Laminin Isoforms and Epithelial Development.”Ann. N.Y. Acad. Sci.857: 194-211.
Fauchère, J.L. et al. (1983) “Hydrophobic Parameters II of Amino-Acid Side Chains from the Partitioning of N-Acetyl-Amino-Acid Amides.”Eur. J. Med. Chem.18(4): 369-375.
Fleischmajer, R. et al. (1998) “There is Binding of Collagen IV to β1 Integrin during Early Skin Basement Membrane Assembly.”Ann. N.Y. Acad. Sci.857:212-227.
Fraga, S., et al. (1990) “Prediction of the Secondary Structure and Functional Sites of Major Histocompatibility Complex Molecules.”J. Mol. Recognit.3(2): 65-73.
Friedl, P., et al. (1998) “Integrins, Cell Matrix Interactions and Cell Migration Strategies: Fundamental Differences in Leukocytes and Tumor Cells.”Cell Adhes. Commun.6(2-3): 225-236.
Fudge, K., et al., (1994) “Immunohistochemistry Analysis of Platelet-derived Growth Factor A and B Chains and Platelet-derived Growth Factor α and β Receptor Expression in Benign Prostatic Hyperplasias and Gleason-graded Human Prostate Adenocarcinomas.”Mod. Pathol.7(5): 549-554.
Fujiwara, H. (1998) “Physiological Roles of Integrin α6β1in Ovarian Functions.”Harm. Res.50(2): 25-29.
Furukawa, F., et al. (1994) “Cadehrins in Cutaneous Biology,”J. Dermatol.21(11):802-813.
Gilewski, T., et al. (2000) “Vaccination of High-Risk Breast Cancer Patients with Mucin-1 (MUCI) Keyhole Limpet Hemocyanin Conjugate Plus QS-211.”Clin. Cancer Res.6(5): 1693-1701.
Giri, D., et al. (1999) “Alterations in Expression of Basic Fibroblast Growth Factor (FGF) 2 and its Receptor FGFR-1 in Human Prostate Cancer1.”Clin. Cancer Res.5(5): 1063-1071.
Goldenberg, D.M. (1993) “Monoclonal Antibodies in Cancer Detection and Therapy.”Am. J. Med.94(3):297-312.
Grasso, A.W., et al. (1997) “ErbB Kinases and NDF Signaling in Human Prostate Cancer Cells.”Oncogene15(22): 2705-2716.
Henderson, R.A., et al. (1998) “Retroviral Expression of MUC-1 Human Tumor Antigen with Intact Repeat Structure and Capacity to Elicit Immunity In Vivo.” Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer. Tumor Antigens Regonized by T Cells.J. Immunother.21(4): 247-256.
Hopp, T.P. et al. (1981) “Prediction of Protein Antigenic Determinants from Amino Acid Sequences.”Proc. Natl. Acad. Sci. USA.78(6): 3824-3828.
Hudziak, R.M., et al. (1989) “p185HER3Monoclonal Antibody Has Antiproliferative Effects in Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor.”Mol. Cell Biol.9(3): 1165-1172.
Hussain, R., et al., (1996) “Structure-Function Correlation and Biostability of Antibody CDR-Derived Peptides as Tumour Imaging Agents.”Biomed. Pept. Proteins Nucleic Acids2(3): 67-70.
Katsura, M. et al. (1998) “Overexpression of CD44 Variants 6 and 7 in Human Endometrial Cancer.”Gynecol. Oncol.71(2): 185-189.
Kramer, G., et al. (1995) “High Expression of A CD38-Like Molecule in Normal Prostatic Epithelium and its Differential Loss in Benign and Malignant Disease.”J. Urol.154(5): 1636-1641.
Liapsis, H., et al., (1996) “Integrin αvβ3Expression by Bone Residing Breast Cancer Metastases.”Diagn. Mol. Pathol.5(2): 127-135.
Lohi, J., et al. (1998) “Neoexpression of the Epithelial Adhesion Complex Antigens Thyroid Tumours is Associated

Affiliated with

Also associated with

Rating

Immunogenic cancer peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunogenic cancer peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic cancer peptides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3377850